Dr. Kenneth K. Sakata
A 58-year-old female with a history of a orthotopic heart transplant in 2019 on tacrolimus and mycophenolate, bilateral breast cancer in remission, and follicular thyroid carcinoma status-post total thyroidectomy presented to the pulmonary clinic for evaluation of an enlarging left upper lobe (LUL) pulmonary nodule.
A chest computed tomography (CT) that was ordered two months prior revealed a 16 mm LUL nodule sitting adjacent to the mediastinum. When she returned for a 5-week follow up, the CT showed that the nodule had quickly increased in size to 20 mm. (Fig. 1 & Fig. 2) She was diagnosed with Escherichia Coli from a urinary tract infection 10 days prior to her follow up. A Robotic-Assisted Bronchoscopy (RAB) was ordered to diagnose the growing nodule.
A negative bronchus sign was noted during the initial planning phase of the procedure. Once initialization was achieved, navigation was completed within minutes. Due to the tortuous anatomical location of the nodule, a 270-degree turn was required to access the area of interest. A cavitary nodule was noted under direct visualization with the MONARCH® scope (Fig. 3) negating the need to confirm location with a radial probe ultrasound image. In addition to the robotic-assisted guided needle biopsy, a bronchoalveolar lavage and forceps biopsies were obtained. (Fig. 4) The patient tolerated the procedure without any complications.
The biopsies showed non-necrotizing granulomatous inflammation with histologic features consistent with malakoplakia. (Fig. 5 & Fig. 6) The bacterial cultures from the bronchoalveolar lavage grew Escherichia coli. Susceptibilities from the urine and lung samples were identical. She was treated with a 4-week course of amoxicillinclavulanate. A follow-up chest CT showed that the nodule had decreased in size.
The introduction of Robotic-Assisted Bronchoscopy has made procedures like this successful because of vision and control.
This case highlights the advantages of the MONARCH® platform over conventional bronchoscopy in establishing a diagnosis for a difficult to reach pulmonary lesion. Based on the location of the pulmonary nodule, the risk of bleeding and pneumothorax were felt to be too high via CT guided biopsy. Determining a tissue diagnosis with a lung biopsy was imperative due to the rapidly enlarging nodule and the patient’s underlying history of cancer and immunosuppression. The robotic system is designed to improve peripheral reach, provide direct continuous visualization, and offer precise control of instruments which proved to be superior to other biopsy techniques.
Dr. Sakata is based in Phoenix Arizona. He is board certified in internal medicine,interventional pulmonology, and critical care medicine. His primary focus revolves around bronchoscopy, lung cancer and pleural diseases.
Indications for Use: The MONARCH® Platform and its accessories are intended to provide bronchoscopic visualization of and access to patient airways for diagnostic and therapeutic procedures.
Important Safety Statement: Complications from bronchoscopy are rare and most often minor, but if they occur, may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. It is uncommon for patients to experience other more serious complications (for example, collapsed lung, respiratory failure, heart attack and/or cardiac arrhythmia).
This document reflects the techniques, approaches and opinions of the individual physician. This Auris sponsored document is not intended to be used as a training guide. Other physicians may employ different techniques. The steps demonstrated may not be the complete steps of the procedure. Individual physician preference and experience, as well as patient needs, may dictate variation in procedure steps. Before using any medical device, review all relevant package inserts with particular attention to the indications, contraindications, warnings and precautions, and steps for use of the device(s).
Dr. Kenneth K. Sakata is compensated by and writing on behalf of Auris Health and must present information in accordance with applicable FDA requirements.